Avinger shares fall after Q1 results fail to impress Wall Street
- BySeeking Alpha-
Having initiated the full commercial launch in January, Tigereye sales are likely to increase its combined Lumivascular CTO revenue by 60% YoY in Q1 2021, Avinger (AVGR)...
For Immediate ReleaseChicago, IL – November 18, 2019 - Stocks in this week’s article are Avinger Inc. (NASDAQ:AVGR) , Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) ,...
Avinger, Inc., (Avinger) is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with the peripheral arterial disease (PAD). The Company manufactures and sells a suite of products in the United States and select international markets. Avinger’s products include its Lightbox imaging console, the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO), and Pantheris, an image-guided atherectomy device which is designed to allow physicians to precisely remove arterial plaque in PAD patients. The lumivascular platform offers real-time visualization of the inside of the artery during PAD treatment. The lumivascular platform consists of a capital component Lightbox and a range of disposable catheter products, including Ocelot, Ocelot PIXL, Ocelot MVRX and Pantheris.